Close
Solutions
Online Inquiry
Global Services

CAR Targeting Other Cancers and Viral Infection

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Besides the main categories of cancer such as Leukemia, Lymphoma, Carcinoma, Sarcoma, Blastoma and Germ cell tumors, Creative Biolabs also provides world class CAR products targeting other cancers like Glioma, tumor vasculature and even viral infection like CMV or EBV, etc,. Our many years of experience and the most advanced techniques enable us to offer you the first-class products according to your specific requirements.

Glioma is a kind of tumor which arises from glial cells in brain or spine. It can be divided into many types including Ependymomas, Astrocytomas, Oligodendrogliomas, Brainstem glioma, Optic nerve glioma and mixed gliomas. Benefiting from our broad experience in constructing CARs against various glioma antigens, we can offer you the best service.

Tumor regression mechanisms involve targeting both tumor antigen and tumor vasculature which helps tumor grow. Our skilled scientists and technicians have successfully constructed CARs targeting tumor vasculature antigens, including but not limited to KDR, VEGF-R2 and PSMA.

We are pleased to announce Creative Biolabs has successfully constructed different types of bispecific Chimeric Antigen Receptors (Calling Tan CAR) modified T cells approaches which make genetically engineered T cells recognize and target both cancer antigens and latent-virus antigens (such as from attack Cytomegalovirus (CMV), EBV or adenovirus).

In addition to the multiple cancer antigens, elite scientists from Creative Biolabs have successfully placed bispecific Chimeric Antigen Receptors (Calling Tan CAR) targeting cancer antigen grafted with latent-virus antigen in T cells to recognize and attack Cytomegalovirus (CMV) or EBV or adenovirus, which make genetically engineered T cells work better to react to the virus as well as to cancer cells.

CAR Targeting Other Cancers and Viral Infection From MIT news.

Products ordering information

Please note: We guarantee to offer you the best-in-class CARs products which can undoubtedly satisfy various customers' needs. If you are unable to find the item of your choice, please don't hesitate to contact us at any time.

Associated malignancy Target antigen Receptor type Product
Brainstem glioma EGFRvIII scFv-CD28-41BB-CD3ζ CAR-T-3-M315-2BZ
scFv-CD3ζ CAR-T-1-M315-Z
scFv-CD28-FcεRIγ CAR-T-2-M315-2G
Optic nerve glioma VEGFR-2 scFv-CD3ζ CAR-T-1-L341-Z
scFv-CD28-FcεRIγ CAR-T-2-L341-2G
scFv-CD28-41BB-CD3ζ CAR-T-3-L341-2BZ
Autoimmune arthritis C2 scFv-CD28-41BB-CD3ζ CAR-T-3-M304-2BZ
CD37 scFv-CD28-OX40-CD3ζ CAR-T-3-L333-2XZ
EMV-1 TCR-L002
CD1D TCR-L008
Pancreatic cancer PSCA scFv-CD28-41BB-CD3ζ CAR-T-3-L347-2BZ
CLD18A2 scFv-CD28-41BB-CD3ζ CAR-LC200
Mesothelin scFv-41BB-FKBP/41BB-FRB-CD3ζ CAR-LC269
CEA scFv-CD28-OX40-CD3ζ CAR-MZ108
FR+ cancer FITC scFv-CD28-41BB-CD3ζ CAR-T-3-L340-2XZ
Cancer Biotin mcAv/dcAv-FcεRIγ CAR-T-1-M400-G
MUC1-expressing tumors Tn-MUC1 scFv-CD28-CD3ζ CAR-LC128
MUC1 scFv-CD28-41BB-CD3ζ CAR-LC251
CD4 ligands CD4-10-gp120 scFv-CD28-CD3ζ CAR-MZ248
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.